BRST5:Secretory carcinoma: Difference between revisions - Compendium of Cancer Genome Aberrations

(4 intermediate revisions by 2 users not shown)

Line 1:

[[BRST5:Table_of_Contents|Breast Tumours (WHO Classification, 5th ed.)]]

~~{{Under Construction}}~~

(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' ''[[Author_Instructions]]'' ''and [[Frequently Asked Questions (FAQs)|FAQs]] as well as contact your [[Leadership|Associate Editor]] or [mailto:CCGA@cancergenomics.org Technical Support].)''

==Primary Author(s)*==

Hui Chen, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Line 31:

Line 28:

|}

~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~

(''Instructions: The table will have the diagnostic criteria from the WHO book autocompleted; remove any non-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')

~~{| class="wikitable"~~

|+

|WHO Essential Criteria (Genetics)*

|

|-

|WHO Desirable Criteria (Genetics)*

|

|-

~~|Other Classification~~

|

|}

<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home WHO Classification of Tumours].

==Related Terminology==

~~(''Instructions: The table will have the related terminology from the WHO autocompleted.)''~~

{| class="wikitable"

|+

|Acceptable

|

|N/A

|-

|Not Recommended

|

|Juvenile breast carcinoma {4285563}

|}

==Gene Rearrangements==

[[File:ETV6-NTRK3 fusion diagram.tif|left|frameless|655x655px|Gene fusion diagram showing the canonical breakpoints in exon 5 of ''ETV6'' (NM_001987) and exon 15 of ''NTRK3'' (NM_001012338). Alternate fusion breakpoints include exon 4 of ''ETV6'' and exon 14 of ''NTRK3''.]]

{| class="wikitable sortable"

|-

Line 94:

Line 82:

{| class="wikitable sortable"

|-

!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~

!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)

!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~

!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T

!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~

!Established Clinical Significance Per Guidelines - Yes or No (Source)

!~~'''~~Clinical Relevance Details/Other Notes~~'''~~

!Clinical Relevance Details/Other Notes

|-

|

Line 115:

Line 103:

!Chromosomal Pattern

!Molecular Pathogenesis

!~~'''~~Prevalence -~~'''~~

!Prevalence -

~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~

Common >20%, Recurrent 5-20% or Rare <5% (Disease)

!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~

!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T

!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~

!Established Clinical Significance Per Guidelines - Yes or No (Source)

!~~'''~~Clinical Relevance Details/Other Notes~~'''~~

!Clinical Relevance Details/Other Notes

|-

|

Line 131:

Line 119:

==Gene Mutations (SNV/INDEL)==

~~ ~~

{| class="wikitable sortable"

|-

!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~

!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -

~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~

Common >20%, Recurrent 5-20% or Rare <5% (Disease)

!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~

!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T

!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~

!Established Clinical Significance Per Guidelines - Yes or No (Source)

!~~'''~~Clinical Relevance Details/Other Notes~~'''~~

!Clinical Relevance Details/Other Notes

|-

|

Line 178:

Line 165:

==Notes==

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''Associate Editor'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

Prior Author(s):

==References==

(use the "Cite" icon at the top of the page) (''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''''.'')

~~ ~~

<nowiki>*</nowiki>''Citation of this Page'': “Secretory carcinoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Secretory carcinoma</nowiki>.

@@ Line 1: / Line 1: @@
 {{DISPLAYTITLE:Secretory carcinoma}}
 [[BRST5:Table_of_Contents|Breast Tumours (WHO Classification, 5th ed.)]]
-{{Under Construction}}
-<span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)''</span>
 ==Primary Author(s)*==
 Hui Chen, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
@@ Line 31: / Line 28: @@
 |}
-==WHO Essential and Desirable Genetic Diagnostic Criteria==
-<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
-{| class="wikitable"
-|+
-|WHO Essential Criteria (Genetics)*
-|
-|-
-|WHO Desirable Criteria (Genetics)*
-|
-|-
-|Other Classification
-|
-|}
-<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
 ==Related Terminology==
-<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>
 {| class="wikitable"
 |+
 |Acceptable
-|
+|N/A
 |-
 |Not Recommended
-|
+|Juvenile breast carcinoma {4285563}
 |}
 ==Gene Rearrangements==
+[[File:ETV6-NTRK3 fusion diagram.tif|left|frameless|655x655px|Gene fusion diagram showing the canonical breakpoints in exon 5 of ''ETV6'' (NM_001987) and exon 15 of ''NTRK3'' (NM_001012338). Alternate fusion breakpoints include exon 4 of ''ETV6'' and exon 14 of ''NTRK3''.]]
 <br />
 {| class="wikitable sortable"
 |-
@@ Line 94: / Line 82: @@
 {| class="wikitable sortable"
 |-
-!Chr #!!'''Gain, Loss, Amp, LOH'''!!'''Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]'''!!'''Relevant Gene(s)'''
+!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
-!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
+!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
-!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
+!Established Clinical Significance Per Guidelines - Yes or No (Source)
-!'''Clinical Relevance Details/Other Notes'''
+!Clinical Relevance Details/Other Notes
 |-
 |
@@ Line 115: / Line 103: @@
 !Chromosomal Pattern
 !Molecular Pathogenesis
-!'''Prevalence -'''
+!Prevalence -
-'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
+Common >20%, Recurrent 5-20% or Rare <5% (Disease)
-!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T'''
+!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
-!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
+!Established Clinical Significance Per Guidelines - Yes or No (Source)
-!'''Clinical Relevance Details/Other Notes'''
+!Clinical Relevance Details/Other Notes
 |-
 |
@@ Line 131: / Line 119: @@
 ==Gene Mutations (SNV/INDEL)==
-<br />
 {| class="wikitable sortable"
 |-
-!Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -'''
+!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
-'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
+Common >20%, Recurrent 5-20% or Rare <5% (Disease)
-!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  '''
+!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
-!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
+!Established Clinical Significance Per Guidelines - Yes or No (Source)
-!'''Clinical Relevance Details/Other Notes'''
+!Clinical Relevance Details/Other Notes
 |-
 |
@@ Line 178: / Line 165: @@
 <br />
 ==Notes==
-<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''<u>Associate Editor</u>'']] or other CCGA representative.  When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.
 Prior Author(s):
 ==References==
-(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span>
-<br />
 <references />
 <nowiki>*</nowiki>''Citation of this Page'': “Secretory carcinoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Secretory carcinoma</nowiki>.